Will Aytu BioPharma stock go up?

According to Danelfin AI, Aytu BioPharma has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (53.04%) is +2.22% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Aytu BioPharma stock?

The Aytu BioPharma target price is $2.18 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Aytu BioPharma stock right now?

Aytu BioPharma has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (53.04%) is +2.22% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Aytu BioPharma stock is a good buy .

Is Aytu BioPharma undervalued right now?

Based on analysts, the average price target downside for Aytu BioPharma is 0.00% (1Y). According to Danelfin AI, Aytu BioPharma has today an AI Score of 5/10 (Hold Rating).

What was the price range of Aytu BioPharma stock over the past 12 months?

The Aytu BioPharma stock price range over the past 12 months has been $1.71 - $2.9.

What is going on with Aytu BioPharma stock in the last 3 months?

The Aytu BioPharma stock performance in the last quarter has been -17.42%.

Does Aytu BioPharma offer dividend payments?

No, Aytu BioPharma does not currently pay dividends.

What is the current market capitalization of Aytu BioPharma?

Aytu BioPharma's market cap is $23.18M, as of 2026-07-03 08:00.

Aytu Biopharma Inc (AYTU) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

AYTU AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Sentiment+0.91%
How analysts and the market view the stock
Volatility+0.67%
How much the stock price tends to fluctuate
Valuation+0.26%
How the stock is priced relative to its fundamentals
Earnings Quality+0.20%
Stability and reliability of reported earnings
Size & Liquidity+0.20%
Company size and trading liquidity
Momentum+0.14%
Direction and strength of recent price movements

Profitability-0.16%
Profitability and operating efficiency metrics

AYTU probability advantage of beating the market (3M):

+2.22%

Sentiment

Aytu BioPharma (AYTU) has a Sentiment Score of 4/10 because, according to only sentiment analysis, it has a probability advantage of -1.69% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.04%) and the probability of AYTU (48.35%) of overperforming the market in the next 3 months, as determined by Danelfin AI’s sentiment analysis.

Average probability of any US-listed stock of beating the market (3M)50.04%
AYTU probability advantage of beating the market (only sentiment, 3M)-1.69%
AYTU probability of beating the market (3M)48.35%

AYTU probability advantage of beating the market (only sentiment, 3M): -1.69%

The AI-powered sentiment analysis of Aytu BioPharma (AYTU) is only based on the 25 sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of AYTU:

Type	Alpha Signal	Probability Advantage Impact (3M)
Sentiment	Upgrade to Pro to unlock	-1.47%
Sentiment	Upgrade to Pro to unlock	+1.43%
Sentiment	Upgrade to Pro to unlock	-1.40%
Sentiment	Upgrade to Pro to unlock	-1.23%
Sentiment	Upgrade to Pro to unlock	+1.03%
Sentiment	Upgrade to Pro to unlock	+0.81%
Sentiment	Upgrade to Pro to unlock	+0.57%
Sentiment	Upgrade to Pro to unlock	+0.45%
Sentiment	Upgrade to Pro to unlock	-0.40%
Sentiment	Upgrade to Pro to unlock	+0.32%
Sentiment	Upgrade to Pro to unlock	-0.26%
Sentiment	Upgrade to Pro to unlock	-0.25%
Sentiment	Upgrade to Pro to unlock	-0.23%
Sentiment	Upgrade to Pro to unlock	-0.22%
Sentiment	Upgrade to Pro to unlock	-0.21%

Rest of Alpha Signals: -0.65%

AYTU probability advantage of beating the market (only sentiment, 3M)Total:-1.69%
AYTU Sentiment Score

Significant changes Vs previous day

AYTU Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$2.18
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

AYTU Proven Hold Signal & Price Forecast

This is the price chart for AYTU from January 2, 2026 until today. The chart indicates, in yellow, the 61 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

AYTU Average Past Performance & Win Rate

Three months after its 755 Hold signals since July 2026, AYTU had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

755 Past AYTU Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-40.53%
Average Alpha				-51.14%
Win Rate (% Positive Perf.)				24.22%
% Positive Alpha				16.38%

AYTU Frequently Asked Questions

Will Aytu BioPharma stock go up?
According to Danelfin AI, Aytu BioPharma has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (53.04%) is +2.22% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Aytu BioPharma stock?
Is it a good time to buy, sell, or hold Aytu BioPharma stock right now?
Is Aytu BioPharma undervalued right now?
What was the price range of Aytu BioPharma stock over the past 12 months?
What is going on with Aytu BioPharma stock in the last 3 months?
Does Aytu BioPharma offer dividend payments?
What is the current market capitalization of Aytu BioPharma?

Aytu Biopharma Inc Company Profile

Centered around the commercialization of unique therapeutic solutions and consumer healthcare items, Aytu Biopharma, Inc. is a pharmaceutical company operational at both the domestic and international levels. It runs its operations through two primary divisions: the Rx arm and Consumer Health division.

The Rx division offers specific prescription treatments for attention deficit hyperactivity disorder (ADHD). This range includes Adzenys XR-ODT, suitable for patients aged six years and above, along with Cotempla XR-ODT for patients within the age group of six to seventeen years. The section further encompasses pediatric-oriented prescription products such as Karbinal ER — an antihistamine-based extended-release suspension specifically designed to manage several allergic conditions prevalent in patients aged two years or more. Furthermore, it manages Poly-Vi-Flor and Tri-Vi-Flor — prescription fluoride-multivitamin products offered in liquid forms and chewable tablets designed to correct fluoride deficiency in children.

The second arm of Aytu Biopharma falls into the realm of Consumer Health. Here we see their mark made through commercializing a diverse array of over-the-counter medications, personal care goods, as well as dietary supplements catering to hair loss treatment, digestive health maintenance, urological welfare, controlling diabetes, and counteracting allergies. Notably part of their portfolio are Regoxidine - a unique over-the-counter aerosol foam solution offering hair loss treatment for both men and women — plus OmepraCareDR and EsomepraCareDR which are acid morphers aimed at managing frequent heartburn cases.

Additionally interesting is Aytu Biopharma's involvement in developing AR101 (enzastaurin), envisioned as a potent orally administered pioneer small molecule; this serine/threonine kinase inhibitor is targeted towards treating vascular Ehlers-Danlos Syndrome.

Formerly operating under the banner Aytu BioScience Inc., it embraced its current identity Aytu Biopharma, Inc., in March 2021 and since then has operated from its base in Denver, Colorado.

Sector:Health Care
Country:United States
Industry:Pharmaceuticals
Address:7900 E. Union Avenue, Suite 920, Denver
Employees:82
Website:aytubio.com

Pros

Orphan drug designation benefits

Established commercial infrastructure

Revenue diversification across therapeutic areas

Potential for product lifecycle management

Acquisition-driven portfolio expansion

Cons

High research and development expenditure

Regulatory approval uncertainty for pipeline

Patent expiration risk for therapeutics

Reimbursement pressure from healthcare payers

Limited addressable patient populations

Company	AI Score	Compare
AXSMAxsome Therapeutics Inc
OCULOcular Therapeutix Inc
COLLCollegium Pharmaceutical Inc
ADXNAddex Therapeutics Ltd

Company	AI Score	Compare
AXSMAxsome Therapeutics Inc
OCULOcular Therapeutix Inc
COLLCollegium Pharmaceutical Inc
ADXNAddex Therapeutics Ltd

AYTU Stock AI Analysis